- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07223021
소아 및 젊은 성인의 B-세포 급성 림프구성 백혈병에서 플루다라빈 용량 투여에 관한 연구
CAR-T 세포 치료를 위한 림프제거 기간 중 플루다라빈 노출 최적화를 통해 무사건 생존율 향상: B세포 급성 림프모구 백혈병을 가진 소아 및 젊은 성인 대상 무작위 다기관 연구 (INFLUENCE)
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective. The researchers will also look at whether PK-targeted fludarabine dosing is feasible (practical), the side effects of the study treatment, and how the study treatment affects people's quality of life. The researchers will measure quality of life by having participants complete questionnaires.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Kevin Curran, MD
- 전화번호: 1-833-MSK-KIDS
- 이메일: currank@mskcc.org
연구 연락처 백업
- 이름: Jaap Jan Boelens, MD, PhD
- 전화번호: 1-833-MSK-KIDS
연구 장소
-
-
-
Utrecht, 네덜란드
- 모병
- Prinses Máxima Centrum
-
연락하다:
- Friso Calkoen, MD
- 전화번호: +31 88 972 7272
-
-
-
-
-
Münster, 독일
- 모병
- University Children's Hospital Münster
-
연락하다:
- Claudia Rossig, MD
- 전화번호: +49 17641091917
-
-
-
-
New York
-
New York, New York, 미국, 10065
- 모병
- Memorial Sloan Kettering Cancer Center
-
수석 연구원:
- Kevin Curran, MD
-
연락하다:
- Kevin Curran, MD
- 전화번호: 1-833-MSK-KIDS
-
연락하다:
- Jaap Jan Boelens, MD,PhD
- 전화번호: 1-833-MSK-KIDS
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45229
- 모병
- Cincinnati Children's Hospital Medical Center
-
연락하다:
- Christine Phillips, MD
- 전화번호: 513-636-4266
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Children's Hospital of Philadelphia
-
연락하다:
- Regina Myers, MD
- 전화번호: 267-426-0762
-
-
Tennessee
-
Memphis, Tennessee, 미국, 38105
- 아직 모집하지 않음
- St. Jude Children's Research Hospital
-
연락하다:
- Aimee Talleur, MD
- 전화번호: 901-595-4215
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- Texas Children's Hospital
-
연락하다:
- Rayne Rouce, M.D., B.S.
- 전화번호: 832-822-4242
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patients with B-ALL and eligible to receive commercial tisagenlecleucel.
-
Patient's weight > 9 kg at time of lymphodepleting chemotherapy
-
Adequate organ function at time of LD is required and is defined:
- Hepatic: Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia
- Hepatic: AST and ALT < 5x the upper limit of normal for age, unless thought to be leukemic disease-related
- Renal: Calculated glomerular filtration rate (GFR) ≥ 70 ml/min/1.73m^2. (based on Schwartz formula GFR (mL/min/1.73 m²) = (36.2 × Height in cm) / Creatinine in mg/dL
- Cardiac: LVEF ≥ 50% by multi-gated acquisition scan (MUGA), resting echocardiogram, or cardiac magnetic resonance imaging (MRI) within 6 weeks of screening
- Pulmonary: Oxygen saturation as recorded by pulse oximetry of ≥ 90% on room air
-
Adequate performance status:
- Age ≥ 16 years: ECOG ≤ 1 or Karnofsky > 60% at treatment
- Age < 16 years: Lansky ≥ 60% at treatment
-
Willing to participate as research subject and provide written informed consent from parents/legal representative, patient, and age-appropriate assent as appropriate before any study specific screening procedures are conducted, according to local, regional or national law and legislation.
Exclusion Criteria:
- Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to the study drugs, or drugs chemically related to study treatment or excipients that contraindicate their participation, including fludarabine, cyclophosphamide and tisagenlecleucel.
- Patients with tisagenlecleucel that is deemed out of specification (OOS) will be excluded from this protocol
- Clinically significant active and uncontrolled infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA etc.)
- Patient/parent/guardian unable to give informed consent or unable to comply with the treatment protocol.
- Pregnant or lactating women
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Standard Fludarabine regimen followed by CAR-T
Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4) |
Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4) All patients will receive Cyclophosphamide 500 mg/m2 IV on days -6 and -5 (or -7 and -6). Targeted fludarabine LD: Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg*h/L (range 17.5-18.5mg*h/L) will be infused based on institutional guidelines. |
|
실험적: Targeted fludarabine regimen followed by CAR-T
Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg*h/L (range 17.5-18.5mg*h/L |
Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4) All patients will receive Cyclophosphamide 500 mg/m2 IV on days -6 and -5 (or -7 and -6). Targeted fludarabine LD: Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg*h/L (range 17.5-18.5mg*h/L) will be infused based on institutional guidelines. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
compare the event free survival (EFS )
기간: 28 days
|
EFS is defined as time from randomization until non-response at day 28 after CAR T cell infusion, loss of B-cell aplasia <6 months from the time of CAR T cell infusion, disease relapse, initiation of anti-leukemic therapy or death of any cause |
28 days
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
활착
기간: 2 년
|
2 년
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Kevin Curran, MD, Memorial Sloan Kettering Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 25-072
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .